Literature DB >> 11404430

Endomorphin-1: induction of motor behavior and lack of receptor desensitization.

A Mehta1, G Bot, T Reisine, M F Chesselet.   

Abstract

The endomorphins are recently discovered endogenous agonists for the mu-opioid receptor (Zadina et al., 1997). Endomorphins produce analgesia; however, their role in other brain functions has not been elucidated. We have investigated the behavioral effects of endomorphin-1 in the globus pallidus, a brain region that is rich in mu-opioid receptors and involved in motor control. Bilateral administration of endomorphin-1 in the globus pallidus of rats induced orofacial dyskinesia. This effect was dose-dependent and at the highest dose tested (18 pmol per side) was sustained during the 60 min of observation, indicating that endomorphin-1 does not induce rapid desensitization of this motor response. In agreement with a lack of desensitization of mu-opioid receptors, 3 hr of continuous exposure of the cloned mu receptor to endomorphin-1 did not diminish the subsequent ability of the agonist to inhibit adenylate cyclase activity in cells expressing the cloned mu-opioid receptor. Confirming the involvement of mu-opioid receptors, the behavioral effect of endomorphin-1 in the globus pallidus was blocked by the opioid antagonist naloxone and the mu-selective peptide antagonist Cys(2)-Tyr(3)-Orn(5)-Pen(7) amide (CTOP). Furthermore, the selective mu receptor agonist [d-Ala(2)-N-Me-Phe(4)-Glycol(5)]-enkephalin (DAMGO) also stimulated orofacial dyskinesia when infused into the globus pallidus, albeit transiently. Our findings suggest that endogenous mu agonists may play a role in hyperkinetic movement disorders by inducing sustained activation of pallidal opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404430      PMCID: PMC6762737     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

1.  Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat.

Authors:  W Hauber; S Lutz
Journal:  Behav Brain Res       Date:  1999-12       Impact factor: 3.332

2.  High-dose naloxone in tardive dyskinesia.

Authors:  J P Lindenmayer; E Gardner; E Goldberg; L A Opler; S R Kay; H M van Praag; M Weiner; S Zukin
Journal:  Psychiatry Res       Date:  1988-10       Impact factor: 3.222

Review 3.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

4.  Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.

Authors:  K Raynor; H Kong; Y Chen; K Yasuda; L Yu; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1994-02       Impact factor: 4.436

5.  Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level.

Authors:  J M Delfs; H Kong; A Mestek; Y Chen; L Yu; T Reisine; M F Chesselet
Journal:  J Comp Neurol       Date:  1994-07-01       Impact factor: 3.215

6.  Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus.

Authors:  D Dewar; P Jenner; C D Marsden
Journal:  Neuroscience       Date:  1985-05       Impact factor: 3.590

7.  Differential opioid agonist regulation of the mouse mu opioid receptor.

Authors:  A D Blake; G Bot; J C Freeman; T Reisine
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

8.  Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum.

Authors:  M Matsumura; L Tremblay; H Richard; M Filion
Journal:  Neuroscience       Date:  1995-03       Impact factor: 3.590

9.  Endomorphin-1 and endomorphin-2 are partial agonists at the human mu-opioid receptor.

Authors:  K Hosohata; T H Burkey; J Alfaro-Lopez; E Varga; V J Hruby; W R Roeske; H I Yamamura
Journal:  Eur J Pharmacol       Date:  1998-04-03       Impact factor: 4.432

Review 10.  The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia.

Authors:  A J Stoessl; E Polanski; H Frydryszak
Journal:  Mov Disord       Date:  1993-10       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.